ArticleThe oncologist2025

Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.

Yu Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.